| View |
|
DRP-13984-02
|
Apixaban
|
Profixamed
|
2.5 mg
|
Film-Coated Tablet
|
Antithrombotic agent (Direct factor Xa inhibitor)
|
Stallion Laboratories Pvt. Ltd
|
India
|
CLIDP Conversion
|
06 February 2024
|
31 May 2028
|
| View |
|
DRP-13984-03
|
Apixaban
|
Abanvex 2.5
|
2.5 mg
|
Film-Coated Tablet
|
Antithrombotic agent (Direct factor Xa inhibitor)
|
Stallion Laboratories Pvt. Ltd
|
India
|
CLIDP Conversion
|
20 February 2024
|
31 May 2028
|
| View |
|
DRP-13986-01
|
Apixaban
|
Xabitor 5
|
5 mg
|
Film-Coated Tablet
|
Antithrombotic agent (Direct factor Xa inhibitor)
|
Intas Pharmaceuticals Limited
|
India
|
CLIDP Conversion
|
15 February 2024
|
31 May 2028
|
| View |
|
DRP-14010-01
|
Cefixime (as trihydrate)
|
Triocef
|
400 mg
|
Film Coated Tablet
|
Antibacterial (Third-generation Cephalosporin)
|
Innova Captab Ltd. (Unit II)
|
India
|
CLIDP Conversion
|
21 January 2024
|
05 June 2028
|
| View |
|
DRP-14013-01
|
Atorvastatin (As Calcium)
|
Gotorvast 40
|
40 mg
|
Film-Coated Table
|
Lipid Modifying Agent (HMG CoA Reductase Inhibitor)
|
Hebei Tiancheng Pharmaceutical Co., Ltd
|
China
|
CLIDP Conversion
|
19 January 2024
|
06 June 2028
|
| View |
|
DRP-14014-01
|
Atorvastatin (as Calcium)
|
Gotorvast 20
|
20 mg
|
Film-Coated Tablet
|
Lipid Modifying Agent (HMG CoA Reductase Inhibitor)
|
Hebei Tiancheng Pharmaceutical Co., Ltd.
|
China
|
CLIDP Conversion
|
22 January 2024
|
06 June 2028
|
| View |
|
DRP-14015-01
|
Atorvastatin (As Calcium)
|
Gotorvast 10
|
10 mg
|
Film-Coated Tablet
|
Lipid Modifying Agent (HMG CoA Reductase Inhibitor)
|
Hebei Tiancheng Pharmaceutical Co., Ltd.
|
China
|
CLIDP Conversion
|
19 January 2024
|
06 June 2028
|
| View |
|
DRP-14017-1
|
Salbutamol (as sulfate) + Guaifenesin
|
Mucoaire
|
1 mg / 50 mg per 5 mL
|
Syrup
|
Expectorant / Anti-Asthma
|
Enicar Pharmaceuticals Pvt. Ltd
|
India
|
CLIDP Conversion
|
22 February 2024
|
06 June 2028
|
| View |
|
DRP-14019-02
|
Co-Amoxiclav
|
Prevaclav 457
|
457 mg/ 5 mL
|
Powder for Suspension
|
Antibacterial (Penicillins)
|
Indchemie Health Specialities Private Limited
|
India
|
CLIDP Conversion
|
14 February 2024
|
06 June 2028
|
| View |
|
DRP-14038-01
|
Apixaban
|
Xabitor 2.5
|
2.5 mg
|
Film-Coated Tablet
|
Antithrombotic agent (Direct factor Xa inhibitor)
|
Intas Pharmaceuticals Limited
|
India
|
CLIDP Conversion
|
15 February 2024
|
07 June 2028
|
| View |
|
DRP-14065-05
|
Ceftriaxone (as sodium)
|
Axonex
|
1 g
|
Powder for Injection (IM/IV)
|
Antibacterial (Cephalosporin)
|
Swiss Parenterals Ltd
|
India
|
CLIDP Conversion
|
06 February 2024
|
13 June 2028
|
| View |
|
DRP-14162-01
|
Polymyxin B (as sulfate)
|
Colymyx
|
500,000 Units
|
Powder for Solution for Injection (Intrathecal /IM/IV)
|
Antibacterial
|
Swiss Parenterals Ltd.
|
India
|
CLIDP Conversion
|
19 February 2024
|
06 July 2028
|
| View |
|
DRP-14170-01
|
Enzalutamide
|
Enzalutech
|
40 mg
|
Capsule
|
Androgen Receptor Antagonist
|
Globela Pharma Private Limited
|
India
|
CLIDP Conversion
|
12 February 2024
|
01 August 2028
|
| View |
|
DRP-14172-01
|
Clindamycin (as phosphate)
|
Clindaseph
|
150 mg / mL
|
Solution for Injection (IM/IV)
|
Antibacterial (Lincosamide)
|
Samrudh Pharmaceuticals Pvt. Ltd.
|
India
|
CLIDP Conversion
|
21 February 2024
|
13 July 2028
|
| View |
|
DRP-14222-01
|
Mupirocin
|
None
|
20 mg / g (2 % w/w)
|
|
Antibacterial for Topical Use
|
Lloyd Laboratories, Inc.
|
Philippines
|
CLIDP Conversion
|
22 January 2024
|
24 July 2025
|
| View |
|
DRP-14268-02
|
Mupirocin
|
Bacterase
|
20 mg / g (2% w/w)
|
Ointment
|
Antibacterial
|
Magbro Healthcare Pvt. Ltd.
|
India
|
CLIDP Conversion
|
23 February 2024
|
07 February 2025
|
| View |
|
DRP-14354-01
|
Salbutamol (as sulfate)
|
Salbpress
|
100 mcg/actuation
|
Pressurized Metered-Dose Inhaler
|
Selective Beta-2-Adrenoreceptor Agonist
|
Jewim Pharmaceutical (Shangdong) Co., Ltd
|
China
|
CLIDP Conversion
|
14 February 2024
|
24 August 2028
|
| View |
|
DRP-14374-02
|
Cilostazol
|
None
|
50 mg
|
Tablet
|
Antithrombotic Agent (Platelet aggregation inhibitor)
|
Cooper Pharma Limited
|
India
|
CLIDP Conversion
|
16 January 2024
|
30 August 2028
|
| View |
|
DRP-14375-02
|
Dutasteride + Tamsulosin Hydrochloride
|
None
|
500 mcg/400 mcg
|
Capsule
|
Benign Prostatic Hypertrophy Drug (Alpha-adrenoreceptor antagonist)
|
Pell Tech Healthcare Private Ltd.
|
India
|
CLIDP Conversion
|
01 March 2024
|
31 August 2028
|
| View |
|
DRP-14387-01
|
Telmisartan
|
None
|
80 mg
|
Tablet
|
Angiotensin II Receptor Blocker (ARB)
|
Lloyd Laboratories, Inc
|
Philippines
|
CLIDP Conversion
|
22 January 2024
|
31 August 2028
|